Assessment of subtle cognitive impairments in patients with post-COVID syndrome with the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus).

Kozik, V.[a1], Reuken, P.[b], Utech, I.[a], Gramlich, J.[b], Stallmach, Z.[b], Demeyere, N[c]., Stallmach, A.[2b,d], Finke, K.[2ae]

[a]Department of Neurology, Jena University Hospital/Friedrich-Schiller-University Jena, Jena, Germany

[b]Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases), Jena University Hospital/Friedrich-Schiller-University Jena, Am Klinikum 1, 07743 Jena, Germany

c: Department of Experimental Psychology, University of Oxford, Radcliffe Observatory Quarter, Oxford OX2 6GG, UK

d: Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany

e: Department of Psychology, Ludwig-Maximilians-Universität München

[1] corresponding author

[2] shared senior authorship

Words: 3,598

Abstract

Background and objectives. Cognitive symptoms persisting beyond 3 months following COVID-19 present a considerable disease burden. We aimed to establish a domain-specific cognitive profile of post-COVID syndrome, and relationships with clinical variables, to provide relevant information for outcome prediction and treatment decision-making.

Methods. We compared cognitive performance on the Oxford Cognitive Screen-Plus between a large post-COVID cohort (n = 282) and a socio-demographically matched healthy control group (n = 52). We assessed task- and domain-level dysfunction and relationships between clinical and patient-reported outcomes.

Results. Patients scored significantly lower on delayed verbal memory, attention, and executive functioning than healthy controls and in each of these domains, 10-20% of patients scored below cutoff. Delayed Memory was particularly affected and a rather small proportion of its variace was explained by hospitalization (β = -.67, p < .01) and age (β = -.03, p < .01; R^2adj. = .06). Hospitalization further predicted attention performance (β = -.83, p < .001; R^2adj. = .04).

Interpretation. Post-COVID syndrome is associated with long-term cognitive dysfunction, particularly in delayed verbal memory, attention, and executive functioning, relatively independent of original disease severity. Next, longitudinal investigation of the domain-dysfunctions in this cohort is needed to examine their trajectory.

1 Introduction

A considerable number of individuals affected by coronavirus disease 2019 (COVID-19), including mild and asymptomatic cases, suffer from long COVID. They often report long-term cognitive effects, in addition to fatigue and physical (e.g., dyspnea, pain) symptoms [1-4]. If symptoms that develop during or after a COVID-19 infection, persist for more than 12 weeks and cannot be explained by another diagnosis, the patient suffers from post-COVID-19 syndrome (see NICE guidelines: [5]). A recent study on a large group of 355 patients from a post-COVID outpatient clinic, found that more than 90% reported signs of fatigue and depression, and that in 23% the 26-point cutoff of the Montreal Cognitive Assessment indicated cognitive dysfunction ([6]; for similar results see [7], for meta-analysis see [8]). Interestingly, among these symptoms, only cognitive dysfunction according to the MoCA was associated with the severity of acute COVID-19, i.e., more frequent in hospitalized than in non-hospitalized patients. Such cognitive deficits are of particular relevance, as they have a strong impact on patients' daily functioning, employment, and the ability to return to work, and, thus, constitute a large disease burden [9]. Consistent with frequently reported cognitive dysfunction after COVID-19, MRI data from the UK Biobank reveals, that participants who contracted COVID-19 between scans showed more pronounced overall brain volume reduction and specifically grey matter thickness reduction in left orbitofrontal cortex and parahippocampal gyrus, than non-affected participants [10]. Given the established presence of impaired performance on the MoCA in a considerable number of patients with post-COVID syndrome, the next important step is to establish their specific neuropsychological profile. A characterization of impaired and preserved cognitive domains could contribute to a better understanding of the underlying pathogenic mechanisms, facilitate individual cognitive outcome prediction, and inform treatment decisions by indicating the target domain for cognitive interventions. Neither short cognitive screens with an overall cutoff, such as the MoCA, nor exclusively subjective patient reports of cognitive problems are able to elucidate domain-specific cognitive profiles. A few studies have already used comprehensive neuropsychological batteries in relatively small samples of patients with long-lasting symptoms following COVID-19. They revealed relatively low performance, especially on attentional, executive functioning, and memory measures, compared to standard norms [11-13]. However, these studies

included patients at heterogeneous stages of disease and recovery, not necessarily fulfilling the 12-weeks post-infection criterion. Furthermore, they did not include healthy control groups. Thus, it is unclear to which degree the deficits could be related to heightened psychological stress under the conditions of a pandemic, rather than to the infection itself. Finally, the use of comprehensive batteries is time-consuming with respect to application, scoring, and interpretation, and requires specialized neuropsychological staff, and they are thus not easily scalable to the assessment of larger patient groups. The present study used a time- and cost-effective alternative to meet this demand. The Oxford Cognitive Screen-Plus (OCS-Plus; [14]) is an innovative tablet-based screening tool which enables the assessment of domain-specific cognitive functions and to establish a profile of preserved and impaired functions. Its use requires little training from operating staff, outcome measures are scored automatically, rendering it particularly advantageous in the context of large cohorts. The good psychometric properties of the OCS-Plus allow for the detection of even subtle cognitive deficits in subclinical and clinical populations [14, 15].

Thus, the first aim of this study was to provide a domain-specific assessment of cognitive deficits associated with post-COVID syndrome via the use of the OCS-Plus in a large sample in order to characterize the neuropsychological profile of impaired and preserved cognitive functions. The second aim was to establish the relationships of cognitive deficits with relevant clinical variables. In order to reach these aims, patients of the interdisciplinary post-COVID center at the Jena University Hospital and a socio-demographically matched healthy control group were assessed with the OCS-Plus and their results in different cognitive domains were compared. Based on results obtained in smaller patient samples at heterogeneous recovery stages [11, 12], we expected to find differences in the domains of memory, attention, and executive functioning. Furthermore, we assessed the percentage of patients showing impaired performance (as indicated by scores of more than 1.5 SDs below the control data mean) in one, two, or three cognitive domains. Finally, we tested how potential cognitive dysfunctions are related to subjective cognitive complains, depression, fatigue, initial disease severity, and age.

2 Methods

2.1 Participants

A total of 282 patients fulfilling the NICE criteria for post-COVID-syndrome and 52 healthy controls were included in this study. Participants in the post- COVID sample presented to the post-COVID clinic at Jena University Hospital between August 2020 and March 2022. Participants were included in this study if they were aged 18-65 years, willing and able to give informed consent, and capable of taking part in the assessment. General exclusion criteria were prior history of relevant neurological disorders potentially impairing cognition, substance use disorder, and relevant vision and hearing problems. The study was approved by the ethics committee of the Friedrich-Schiller-University [amendment to 5082-02/17].

2.2 Assessment

Patients underwent structured anamnesis including the patient's medical history, basic socio-demographic data, and subjective cognitive complaints. All participants completed the depression module of the Patient Health Questionnaire (PHQ-9; [16]), the Fatigue Assessment Scale (FAS; [17]) and the Brief Fatigue Inventory (BFI; [18]). Cognitive function was assessed using the Oxford Cognitive Screen-Plus [14]. The OCS-Plus consists of 10 subtasks, assessing the cognitive domains of orientation, memory, attention, and executive functions and takes approximately 25 minutes. Tasks were completed using a stylus pen on a tablet computer. From the OCS-Plus subtasks, six domain scores may be calculated: Naming and semantic understanding (picture Naming + semantics), memory encoding (encoding 1 + encoding 2), delayed memory (delayed recall + delayed recall and recognition), praxis (figure copy + figure recall), attention (cancellation + invisible cancellation), and executive functioning (trails executive score - cancellation false positives; [14])[1]. Detailed descriptions of all tasks and derived measures are available in the supplemental material and in Demeyere et al. (2021).

2.3 Statistical Analysis

[1] Due to time constraints in the clinical setting, the OCS-Plus subtask "rule finding" was skipped. Accordingly, scoring for executive functioning differs from the method proposed by Demeyere et al. (2021).

We compared socio-demographic variables between patients and healthy controls using t-tests with Welch correction to account for the difference in sample sizes, and a chi-squared test with Yates' continuity correction to compare sex ratios. Groups were compared on the BFI and the PHQ-9 using Welch two sample t-tests. Performance on the OCS-Plus subtasks and overall domain scales was compared between patients and controls using Wilcoxon rank sum tests with continuity correction. As we expected patients to perform worse on memory, attentional, and executive functioning tasks, we used one-tailed tests with an alpha level of .05. We then examined how many patients fell below a cut-off of 1.5 standard deviations below the healthy control sample on the domain scales of interest. To take into account the heterogeneity of symptoms and particularly of cognitive complaints, we split patients into two groups: those who complain of both memory and concentration problems (high complainers) and those who report only one or none of these symptoms (low complainers). These groups were then compared in terms of their cognitive performance on the domain scales of the OCS-Plus. We controlled for a false discovery rate of 5% among tests concerning the cognitive domains of interest (i.e., memory, attention, and executive functioning), using the Benjamin-Hochberg method. To explore predictors of attentional, memory, and executive functioning problems as part of post-COVID syndrome, we performed multiple linear regression analyses within the patient group. Based on the reported comparisons and findings reported in previous studies, we included initial disease severity, as categorized by need for hospitalization (i.e., outpatient versus inpatient treatment) and age as predictors of performance on the OCS-Plus. An average 0.12% of data points are missing for each score due to technical difficulties. Analysis was performed using R version 4.2.0 (R Core Team, 2022).

3 Results

3.1 Sociodemographic and clinical description of post-COVID-19 patients and healthy controls

Basic socio-demographic information for both groups are presented in table 1. There were no differences between groups in terms of age (t = -.76, p = .451), education (t = 1.72, p = .09), or sex ratios (chi-squared = .61, p = .435). Please refer to table 2 for an overview of patient clinical data stratified by hospitalization.

Table 1: Socio-demographic distribution by group

	Controls (n = 52)	Patients (n = 282)	Total (N = 334)
Age			
Mean (SD)	45.62 (10.15)	46.80 (11.27)	46.61 (11.15)
Range	22.00 – 65.00	18.00 – 65.00	18.00 – 65.00
Sex			
Female	31 (59.6%)	186 (66.0%)	217 (65.0%)
Male	21 (40.4%)	96 (34.0%)	117 (35.0%)
Education (years)			
Missing (n)	0	28	28
Mean (SD)	15.28 (1.97)	14.76 (2.07)	14.85 (2.06)
Range	11.00 – 18.00	10.00 – 18.00	10.00 – 18.00

145

Table 2: Clinical data stratified by need for hospitalization

Clinical variable	Distribution	Missingness
Weeks since infection, M (SD)	35.3 (17.1)	0
Outpatient treatment, n (%)	215 (76.2)	0
WHO severity grade, n (%)		1
1	3 (1.4)	
2	210 (98.1)	
3	1 (0.5)	
Inpatient treatment, n (%)	67 (23.8)	0
Hospital stay (days), M (SD)	12 (8.8)	0
Oxygen support, n (%)	48 (71.6)	0
ICU admission, n (%)	22 (33.3)	1
ICU stay (days), M (SD)	3.2 (7.8)	4
WHO severity grade, n (%)		0
2	5 (7.5)	
3	11 (16.4)	
4	25 (37.3)	
5	20 (29.9)	
7	6 (9.0)	

Note. WHO = World Health Organization; ICU = intensive care unit

3.2 Subjective cognitive complains, depression, and fatigue

During the anamnestic interview, 69.9% of patients complained of having attention and 58.9% of memory problems. 55.7% of patients complained of both attention and memory problems. As the two fatigue questionnaires were highly correlated ($r(329) = .78$, $p < .0001$), only the results from the BFI will be used for further analysis. Patients and controls differed in terms of their scores on the BFI ($r = -.46$, $p < .0001$) and on the PHQ-9 ($r = -.44$, $p < .0001$; see table 3 for complete results).

Table 3: Questionnaire data for controls and patients

	Controls				**Patients**				**Wilcoxon rank sum test**		
Questionnaire	**n**	**Mean**	**SD**	**SEM**	**n**	**Mean**	**SD**	**SEM**	***W***	***p***	**r**[a]
BFI	50	2.01	1.54	0.22	281	5.02	2.15	0.13	1811	< .0001	-0.46***
PHQ-9	50	3.92	2.93	0.41	282	10.69	5.57	0.33	2004.5	< .0001	-0.44***

[a] * p<.5; **p<.01; ***p<.001

3.3 Comparison between patients and healthy controls on OCS-Plus subtasks

Patients scored lower than healthy controls on the tasks Encoding 2 ($r = .1$, $p = .034$), Delayed Recall accuracy ($r = .12$, $p = .013$), Figure Copy accuracy ($r = .1$, $p = .037$), Cancellation false positives ($r = -.1$, $p = .03$), and Invisible Cancellation accuracy ($r = .12$, $p = .018$). However, none of the comparisons survived correction. Please refer to table 4 for full results.

Table 4: Performance on the OCS-Plus subtasks per group

	Controls					Patients					Wilcoxon rank sum test		
OCS-Plus task	**n**	**Mean**	**Median**	**SD**	**SEM**	**n**	**Mean**	**Median**	**SD**	**SEM**	**W**	**p**	**r[a]**
Picture naming accuracy	52	3.96	4.00	0.19	0.03	280	3.95	4.00	0.26	0.02	7340	0.397	
Semantics accuracy	51	3.92	4.00	0.27	0.04	282	3.89	4.00	0.33	0.02	7419.5	0.249	
Orientation accuracy	52	3.90	4.00	0.30	0.04	282	3.96	4.00	0.19	0.01	6913	0.962	
Encoding 1	**52**	**4.54**	**5.00**	**0.64**	**0.09**	**274**	**4.52**	**5.00**	**0.66**	**0.04**	**7158.5**	**0.475**	
Encoding 2	**52**	**5.00**	**5.00**	**0.00**	**0.00**	**279**	**4.94**	**5.00**	**0.24**	**0.01**	**7696**	**0.034**	**0.1***
Delayed Recall accuracy	**50**	**3.78**	**4.00**	**1.13**	**0.16**	**279**	**3.24**	**3.00**	**1.48**	**0.09**	**8327**	**0.013**	**0.12***
Delayed Recall and Recognition	**51**	**4.88**	**5.00**	**0.33**	**0.05**	**279**	**4.74**	**5.00**	**0.56**	**0.03**	**7818**	**0.052**	
Episodic Recognition accuracy	**51**	**3.57**	**4.00**	**0.57**	**0.08**	**280**	**3.42**	**4.00**	**0.72**	**0.04**	**7768**	**0.13**	
Processing Speed	**51**	**88.54**	**100.00**	**16.30**	**2.28**	**278**	**82.03**	**92.86**	**24.31**	**1.46**	**7918**	**0.078**	
Trails Executive score	**51**	**16.62**	**14.64**	**7.06**	**0.99**	**278**	**15.03**	**13.39**	**6.91**	**0.41**	**8094**	**0.054**	
Figure Copy accuracy	43	56.98	58.00	2.88	0.44	279	56.39	57.00	2.85	0.17	7002.5	0.037	0.1*
Figure Recall accuracy	42	47.12	47.50	7.98	1.23	279	46.53	48.00	8.43	0.50	6022	0.386	
Cancellation accuracy	**51**	**29.80**	**30.00**	**0.45**	**0.06**	**275**	**29.77**	**30.00**	**0.52**	**0.03**	**7162**	**0.363**	
Cancellation false positives	**51**	**0.04**	**0.00**	**0.20**	**0.03**	**276**	**0.16**	**0.00**	**0.44**	**0.03**	**6390**	**0.03**	**-0.1***
Invisible Cancellation accuracy	**51**	**29.02**	**29.00**	**0.97**	**0.14**	**275**	**28.45**	**29.00**	**1.55**	**0.09**	**8267**	**0.018**	**0.12***
Invisible Cancellation correct revisits	**52**	**1.08**	**0.50**	**1.38**	**0.19**	**276**	**1.43**	**1.00**	**1.91**	**0.11**	**6570**	**0.155**	

[a] (*)significant before correction; (**)significant after correction; bold: subtasks of interest (significance level FDR-corrected)

3.4 Comparison between patients and healthy controls on OCS-Plus domain scales

Patients scored significantly lower than healthy controls on the scales of Delayed Memory (r = .13, p < .01), Executive Functioning (r = .1, p = .033), and Attention (r = .1, p = .027). See table 5 and figure 1 results stratified by group.

Table 5: Performance on the OCS-Plus domain scales per group

	Controls					Patients					Wilcoxon rank sum test		
OCS-Plus scale	**n**	**Mean**	**Median**	**SD**	**SEM**	**n**	**Mean**	**Median**	**SD**	**SEM**	**W**	**p**	**r[a]**
Naming and Semantic Understanding	51	7.88	8	0.38	0.05	280	7.83	8.00	0.44	0.03	7478	0.185	
Memory Encoding	**52**	**9.54**	**10**	**0.64**	**0.09**	**271**	**9.46**	**10.00**	**0.75**	**0.05**	**7296**	**0.322**	
Delayed Memory	**50**	**8.68**	**9**	**1.24**	**0.17**	**279**	**7.98**	**8.00**	**1.77**	**0.11**	**8438.5**	**<0.01**	**0.13****
Praxis	43	103.86	105	8.92	1.36	279	102.92	105.00	9.63	0.58	6189	0.369	
Executive Functioning	**50**	**88.70**	**100**	**16.46**	**2.33**	**275**	**81.59**	**92.86**	**24.79**	**1.49**	**7945**	**0.033**	**0.1****
Attention	**50**	**58.82**	**59**	**1.06**	**0.15**	**275**	**58.22**	**59.00**	**1.72**	**0.10**	**8021**	**0.027**	**0.1****

[a] (*)significant before correction; (**)significant after correction; bold: domain scales of interest (significance level FDR-corrected)



Figure 1: Performance on the OCS-Plus domain scores by controls and patients

3.5 Proportional impairment per group on OCS-Plus domain scales

3.85% of healthy controls and 10.7% of patients scored below the cut-off on Memory Encoding, 6% of healthy controls and 21.15% of patients scored below the cut-off on Delayed Memory, 8% of healthy controls and 19.27% of patients scored below the cut-off on Executive Functioning, and 2% of healthy controls and 14.91% of patients scored below the cut-off on Attention (see figure 2). Out of those patients, for whom there is complete data for all domain scores, 53.7% of patients were impaired on at least one domain score (versus 25% of controls), 18.68% scored below the cut-off on at least 2 domains (versus 5% of controls), and 3.89% scored below the cut-off on at least 3 domains (versus 0% of controls; see figure 2).



Figure 2: Distributions of patients and controls scoring below cutoff on OCS-Plus domain scores

3.6 Relationship between subjective cognitive complaints and OCS-Plus performance

76 patients reported no or only one cognitive symptom and 206 patients reported both attention and memory difficulties. Performance in the Delayed Memory domain differed between those with and without subjective cognitive complaints (W = 8669, p = .024), while there were no significant differences on any other summative scale (see table S1 in the supplemental material for complete results).

3.7 Relationship between clinical variables and OCS-Plus performance

As we did not find any linear relationship between any cognitive measure and BFI or PHQ-9 (see supplemental material) we did not include these as predictors in the regression analyses.

3.7.1 Delayed Memory domain performance

The simple model to predict performance on the Delayed Memory domain score included only hospitalization as a predictor. The overall regression was significant ($F(1, 277) = 12.37$, $p < .001$, R^2adj.= .04) and hospitalization significantly predicted attentional performance (β = -.86, $p < .001$). The second model included both hospitalization and age as predictors. The model was significant ($F(2, 276) = 10.37$, $p < .0001$, R^2adj.= .06) and both predictors were significant (hospitalization: β = -.67, $p < .01$; age: β = -.03, $p = .005$). An ANOVA revealed, that the fit of the second model was better and the R^2 value was significantly higher ($F(1) = 8.05$, $p < .01$. Bootstrap (2,000 samples) bias corrected and accelerated confidence intervals for the coefficients in the simple model indicate generalizability of the model (intercept: [8.54; 10.19], hospitalization: [-1.19; -.21], age: [-.04; -.01]).

3.7.2 Attention domain performance

The first, simple linear model to test whether hospitalization significantly predicted attentional performance was significant ($F(1, 273) = 12.11$, $p < .001$, R^2adj..= .04) and hospitalization significantly predicted attentional performance (β = -.83, $p < .001$). A second model including age as a predictor was also significant ($F(2, 272) = 7.56$, $p < .001$ and hospitalization was a significant predictor (β = -.72, $p < .01$) of attentional performance. However, age was not significant (β = -.02, $p = .089$) and comparing the two models using an ANOVA, there was no added benefit of this less parsimonious model including age ($p = .089$). Bootstrap (2,000 samples) bias corrected and accelerated confidence intervals for the coefficients in the simple model indicate generalizability of the model (intercept: [58.19;

58.62], hospitalization: [-1.44; -.32]). Please refer to tables S2 and S3 in the supplemental material for full results of the models.

3.7.3 Executive Function domain performance

We fitted two models to predict executive functioning using the predictors of hospitalization alone and hospitalization and age. Neither model was significant (simple model: $F(1, 273) = 1.4$, $p = .237$; multiple model: $F(2, 272) = .71$, $p = .242$).

4 Discussion

In this study, preserved basic orientation, language, and visuo-spatial functions and subtle, but meaningful impairments in attention, delayed memory and executive functions were identified in patients with post-COVID syndrome. This neuropsychological profile fits with results of previous studies with comprehensive test batteries in smaller patient samples assessed at various stages, ranging from post-acute to post-COVID time scales [11, 12]. Notably, in the present study, the use of the highly scalable, time-economic tablet-based OCS-Plus [14] delivering automated scoring allowed the assessment of a substantially larger patient sample fulfilling the NICE criterion of symptom persistence of more than 12 weeks post-infection. As opposed to these previous studies, the use of a socio-demographically matched control group in the present study allowed to infer that the identified cognitive deficits were not just related to generally heightened psychological stress during the current pandemic. In each of the affected domains i.e., delayed memory, attention, and executive functioning, between 10 and 20% of patients fell below a cutoff of 1.5 standard deviations based on the healthy group distribution. In fact, a substantial number of patients showed domain-level deficits, as more than half of patients scored below the cutoff in at least one major domain score and just under a fifth of patients in at least two major domain scores. Such deficits were found most often in the delayed verbal memory domain. This is in line with the finding of left-sided parahippocampal gyrus atrophy in individuals affected by SARS-COV-2 [10, 19].

Interestingly, memory is also the cognitive domain which differed between patients with post-COVID-syndrome with high vs. low subjective cognitive complains. Thus, particularly the deficits in delayed memory seem to be relevant for patients' subjective daily life impairment.

Our regression analyses showed a small influence of initial disease severity, as categorized by need for hospitalization, on memory and attentional performance, with a marginal impact of age on memory performance. Thus, hospitalized patients seem to be somewhat more impaired in delayed memory and attentional performance than non-hospitalized patients. These finding is basically in line with findings of relationships between the severity of the acute illness and cognitive deficits in small samples of either subacute patients [20] or patients at heterogeneous stages of disease recovery [11, 21]. Similarly, they are in principle also in accordance with a trend for higher incidences of pathological MOCA scores in previously hospitalized vs. non-hospitalized post-COVID patients of the Jena outpatient post-COVID clinic [6]. In the current study, the predictive power of initial disease severity was rather low. As this was also true for the predictive power of age, the main message from the regression analyses is that, essentially all patients, regardless of age and severity of the acute infection, can show long-term deficits for more than 3 months following SARS-CoV-2 infection.

As expected based on previous studies (e.g. [6, 11]), patients also differed from socio-demographically matched controls in terms of fatigue and depression. However, as we did not find an association between the severity of fatigue and depression and cognitive performance in this large patient cohort, the results might indicate that cognitive deficits after SARS-CoV-2 infection are a separate entity. This would be in line with previous findings, that only cognitive deficits but not fatigue and depression are associated with severity of the acute infection [6].

The study has certain strengths and multiple limitations. Strengths include a large sample of well-defined post-COVID patient group, a socio-demograpically matched control group and

the use of an innovative and sensitive tablet-based assessment tool with automated scoring. The most critical limitation is that our study cannot inform about whether the identified deficits pre-existed prior to infection. This is true even though we excluded patients with known relevant neurological disorders. Our study is furthermore prone to selection bias. As we tested a clinically referred sample of post-COVID patients, findings might not generalize to all post-COVID patients, but only to those who have symptoms severe enough to visit a specialized clinic.

The OCS-Plus testing identified subtle long-term cognitive deficits persisting for more than 3 months in patients with post-COVID syndrome. A relevant next step will be obtain longitudinal data on memory, attention and executive functions from the presented cohort, in order to differentiate between deficits that might improve and those that might become chronic. This will provide specific information on targets for interventions, such as cognitive training. As many patients affected by post-COVID syndrome are living in medically underserved, rural areas, the mobile, cost-effective and highly scalable OCS-Plus assessment could be used for testing patients outside specialized facilities.

Funding

The post-COVID Center was supported by the Thüringer Aufbaubank (2021 FGI 0060).

Conflict of interest

All authors report no conflict of interest regarding the content of the manuscript.

Author contributions

VK: Writing – original draft, data curation, formal analysis, data collection. PR: Conceptualization & implementation, writing – critical review. IU: data collection. JU: data collection. ZS: data collection. ND: Methodology. AS: Conceptualization, supervision, resources, writing – critical review. KF: Conceptualization, supervision, resources, writing – critical review and editing

Acknowledgments

We would like to thank our student assistants Lara Gutfleisch and Antonia Haddenhorst for their contributions to data collection.

References

1. Guo, P., et al., *COVCOG 1: Factors predicting Cognitive Symptoms in Long COVID. A First Publication from the COVID and Cognition Study.* medRxiv, 2021: p. 2021.10.26.21265525.

2. Lund, L.C., et al., *Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study.* The Lancet Infectious Diseases, 2021. **21**(10): p. 1373-1382.

3. Nalbandian, A., et al., *Post-acute COVID-19 syndrome.* Nature Medicine, 2021. **27**(4): p. 601-615.

4. Reuken, P.A., A. Scherag, and A. Stallmach, *Postcoronavirus Disease Chronic Fatigue Is Frequent and Not Only Restricted to Hospitalized Patients.* Critical Care Medicine, 2021. **49**(10): p. e1052.

5. Sivan, M. and S. Taylor, *NICE guideline on long covid.* BMJ, 2020. **371**: p. m4938.

6. Stallmach, A., et al., *Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation?* Infection, 2022.

7. Boesl, F., et al., *A Neurological Outpatient Clinic for Patients With Post-COVID-19 Syndrome — A Report on the Clinical Presentations of the First 100 Patients.* Frontiers in Neurology, 2021. **12**.

8. Lopez-Leon, S., et al., *More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.* Scientific Reports, 2021. **11**(1): p. 16144.

9. Davis, H.E., et al., *Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.* eClinicalMedicine, 2021. **38**.

10. Douaud, G., et al., *SARS-CoV-2 is associated with changes in brain structure in UK Biobank.* Nature, 2022. **604**(7907): p. 697-707.

11. Bungenberg, J., et al., *Long COVID-19: Objectifying most self-reported neurological symptoms.* Annals of Clinical and Translational Neurology, 2022. **9**(2): p. 141-154.

12. García-Sánchez, C., et al., *Neuropsychological deficits in patients with cognitive complaints after COVID-19.* Brain and Behavior, 2022. **12**(3): p. e2508.

13. Graham, E.L., et al., *Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers".* Annals of Clinical and Translational Neurology, 2021. **8**(5): p. 1073-1085.

14. Demeyere, N., et al., *Introducing the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus) as an assessment tool for subtle cognitive impairments.* Scientific reports, 2021. **11**(1): p. 1-14.

15. Humphreys, G.W., et al., *Cognitive Function in Low-Income and Low-Literacy Settings: Validation of the Tablet-Based Oxford Cognitive Screen in the Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI).* The Journals of Gerontology: Series B, 2016. **72**(1): p. 38-50.

16. Kroenke, K., R.L. Spitzer, and J.B.W. Williams, *The PHQ-9.* Journal of General Internal Medicine, 2001. **16**(9): p. 606-613.

17. de Vries, J., et al., *Measuring fatigue in sarcoidosis: The Fatigue Assessment Scale (FAS).* British Journal of Health Psychology, 2004. **9**(3): p. 279-291.

18. Mendoza, T.R., et al., *The rapid assessment of fatigue severity in cancer patients.* Cancer, 1999. **85**(5): p. 1186-1196.

19. Squire, L.R. and S. Zola-Morgan, *The medial temporal lobe memory system.* Science, 1991. **253**(5026): p. 1380-1386.

20. Hosp, J.A., et al., *Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.* Brain, 2021. **144**(4): p. 1263-1276.

21. Chamberlain, S.R., et al., *Post-traumatic stress disorder symptoms in COVID-19 survivors: online population survey.* BJPsych open, 2021. **7**(2).